NIMHANS Study: Yoga Halves Opioid Withdrawal Time to 5 Days

A joint randomized clinical trial from NIMHANS in Bengaluru and Harvard Medical School has produced what may be the most statistically compelling argument yet for yoga's place inside addiction medicine: men with opioid use disorder who practiced yoga alongside standard buprenorphine treatment stabilized from withdrawal in a median of five days, compared to nine days for those on medication alone, a hazard ratio of 4.40.

The trial, led by Suddala Goutham of NIMHANS's Department of Integrative Medicine and published in JAMA Psychiatry on January 7, enrolled 59 male inpatients between 18 and 50 years old at the Centre for Addiction Medicine's inpatient ward. Participants were tracked from April 2023 through March 2024, with 29 assigned to yoga as an add-on to buprenorphine and the remaining 30 receiving medication with standard psychosocial support and counselling. The primary opioid misused was tapentadol.

The yoga protocol was not open-ended practice. It was a validated, structured 45-minute module delivered across 10 supervised sessions over 14 days, led by trained instructors. Each session moved through five standardized components: guided relaxation, mindful asanas, sectional breathing, pranayama techniques including left-nostril breathing and bhramari, and abbreviated yoga nidra with positive affirmations. The sequence was built specifically to counter sympathetic nervous system hyperactivity, the neurological driver of withdrawal symptoms including insomnia, anxiety, vomiting, sweating, and pain.

The autonomic data bore this out. The yoga group showed large-effect improvements in heart rate variability (HRV), a direct measure of nervous system balance, across low-frequency power, high-frequency power, and the LF/HF ratio, all statistically significant at p less than 0.001. Mediation analysis confirmed that parasympathetic reactivation was the mechanism linking yoga to faster stabilization. Secondary measures showed improvements in anxiety, sleep quality, and pain scores as well.

"In this trial, yoga significantly enhanced opioid withdrawal recovery through measurable autonomic and clinical improvements, supporting its integration into withdrawal protocols as a neurobiologically informed intervention," said Goutham. Dr. Hemant Bhargav, who led the research at NIMHANS, added that yoga "helps calm the body's stress response, which goes into overdrive during withdrawal."

The scale of the problem gives those numbers weight. An estimated 60 million people worldwide used opioids nonmedically in 2022, yet only one in 11 people with drug use disorders received treatment. In India, a 2019 national survey put opioid use prevalence at 2.1 percent, with markedly higher rates in north-eastern states.

For practitioners and families navigating opioid withdrawal, the findings carry a clear and critical qualifier: the yoga in this trial was not self-directed home practice. It was inpatient, supervised by trained instructors, and run as an adjunct to buprenorphine, not a substitute for it. The trial enrolled only men, so generalizability across genders remains untested. Whether the protocol translates to outpatient or community clinic settings is also unconfirmed and requires further study. The practical footprint is low, a quiet room, mats, and a certified instructor, but the medical supervision is non-negotiable.

Families supporting someone through opioid withdrawal should ask their treatment provider whether a supervised yoga adjunct program is available at their facility, confirm it runs alongside prescribed medication rather than replacing it, and verify that sessions are delivered by instructors trained in therapeutic yoga rather than general fitness classes.

With this trial, yoga moves from promising complement to evidence-backed clinical tool, provided the clinical scaffolding stays intact.